AstraZeneca (AZN LN) CEO says we do not need new deals in weight loss, drug prices in the US will come down but Europe's must rise

AstraZeneca's CEO indication that the company doesn't seek new deals in weight loss signals confidence in their current pipeline and strategic focus.

Newsquawk StaffPublished On the live feed at 1 more headline followed before this page went public
Newsquawk headlinesUTC

European Movers: Philips (PHIA NA) +9.5%, Kering (KER FP) +8.8%, Bellway (BMY LN) +3.4%, Barclays (BARC LN) +1.1%, BP (BP/ LN) -2.7%, TUI (TUI GY) -2.7%

Alphabet (GOOGL) launches its first CHF debt sale, according to Bloomberg

AstraZeneca (AZN LN) CEO says we do not need new deals in weight loss, drug prices in the US will come down but Europe's must rise

Rolls-Royce (RR/ LN) launches modular gas engine power plants

[MARKET UPDATE] Volatility in FTSE 100 Mar'26 futures amid earnings from index-heavyweights BP, AstraZenca, and Barclays; contract spiked higher at 07:00 GMT (from 10,371 to 10,403) before paring the entire move over 10 minutes

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

The comments on drug prices suggest a strategic pivot for the U.S. market while contrasting with the need for higher prices in Europe, potentially impacting AstraZeneca's competitive positioning and profitability across regions.

Related headlines

The whole workspace, free to try.

Try it free